"10.1371_journal.pone.0056698","plos one","2013-02-22T00:00:00Z","William S Pomat; Anita H J van den Biggelaar; Suparat Phuanukoonnon; Jacinta Francis; Peter Jacoby; Peter M Siba; Michael P Alpers; John C Reeder; Patrick G Holt; Peter C Richmond; Deborah Lehmann; for the Neonatal Pneumococcal Conjugate Vaccine Trial Study Team","Papua New Guinean Institute of Medical Research, Goroka, Papua New Guinea; Telethon Institute for Child Health Research, Centre for Child Health Research, University of Western Australia, Perth, Western Australia, Australia; Centre for International Health, Curtin University, Perth, Western Australia, Australia; Burnet Institute, Melbourne, Victoria, Australia; School of Paediatrics and Child Health, University of Western Australia, Perth, Western Australia, Australia","Conceived and designed the experiments: DL PCR JCR PGH AHvdB MPA. Performed the experiments: JF. Analyzed the data: PJ AHJvdB. Wrote the paper: DL WSP AHJvdB. Supervised enrollment, clinical follow-up and field work, and reported adverse events to the DSMB: SP. Oversaw conduct of immunological assays and reviewed all immunology data: WSP. Oversaw implementation of the clinical trial and provided administrative support: PMS JCR. Critically read and approved the final version of the manuscript: WSP AHJvdB SP JF PJ PMS MPA JCR PGH PCR DL.","The authors have read the journals policy and have the following conflicts: P Richmond has been a member of vaccine advisory boards for Wyeth and CSL Ltd and has received institutional funding for investigator-initiated research from GlaxoSmithKline Biologicals and Merck and received travel support from Pfizer and Baxter to present study data at international meetings. D Lehmann has been a member of the GSK Australia Pneumococcal-Haemophilus influenzae-Protein D conjugate vaccine (Phid-CV) Advisory Panel, has received support from Pfizer Australia and GSK Australia to attend conferences, has received an honorarium from Merck Vaccines to give a seminar at their offices in Pennsylvania and to attend a conference, and is an investigator on an investigator-initiated research grant funded by Pfizer Australia. WS Pomat has received funding from Pfizer Australia to attend a conference. A.H.J. van den Biggelaar has received support from Pfizer Australia and GSK Australia to attend conferences; she was awarded and received a Pfizer-supported Robert Austrian Award in Pneumococcal Vaccinology (2008); she is currently an employee of Crucell/Johnson and Johnson, The Netherlands. All work related to this publication was conducted prior to employment at Crucell/Johnson and Johnson. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials. S Phuanukoonnon, J Francis, P Jacoby, PM Siba, JC Reeder, MP Alpers and Patrick G Holt have declared that no competing interests exist. Vaccines used in this trial were purchased from manufacturers.","2013","02","William S Pomat","WSP",12,FALSE,NA,NA,NA,NA,NA,NA,NA,NA,NA
